Nowadays, the first-line treatment of patients with lung cancer harbouring a classical EGFR mutation (exon 19 deletion or L858R mutation in exon 21) is usually osimertinib, a third-generation irreversible EGFR TKI, with or without chemotherapy as the first-line therapy [33,34]. This evidence concerns the gene EGFR and lung carcinoma.